NCT02796053View on ClinicalTrials.gov

TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Psoriasis Vulgaris
Interventions
DRUG

TAB08

The TAB08 will be administered intravenously, by infusion.

OTHER

Placebo

The Placebo to TAB08 will be administered intravenously, by infusion.

Trial Locations (1)

150003

Clinical Emergency Hospital of Yaroslavl, Yaroslavl

All Listed Sponsors
lead

Theramab LLC

INDUSTRY

NCT02796053 - TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment | Biotech Hunter | Biotech Hunter